Although RUNX-CBFβ-mediated ILC2 immune responses have not been reported to have direct contributions to anti-tumor immunity, we could speculate that RUNX-CBFβ could indirectly control ILC2 function during anti-tumor immune responses. This evidence concerns the gene CBFB and neoplasm.